ZNTL (Zentalis Pharma) Net earnings per share growth this year

Corporate emblem and logo of Zentalis Pharma (ZNTL)

Zentalis Pharmaceuticals (ZNTL) is developing targeted oncology therapies while remaining in a stage of costly research and regular secondary offerings. The company is expanding partnerships with medical centers to combat cancer cell survival. The proportional growth of EPS compared to last year on the GURU.Markets daily chart shows a value of 5.40, reflecting the current metric amid a stable scientific team and the strategic hiring of compliance experts.

Earnings per share growth in current year: Zentalis Pharmaceuticals, Inc. (ZNTL) for 07/04/2022 - 11/18/2026

Financial and market metric breakdowns for Zentalis Pharma (ZNTL)

- business market valuation indicators:
Basic company analysis:Zentalis Pharmaceuticals
Product sample of Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals (ZNTL) specializes in developing high-precision small molecules for cancer therapy. The growth rate of net income per share compared to last year reflects the commercialization efficiency of these developments. This metric calculates the percentage deviation of the current EPS from the same period last year, capturing the real acceleration of the business. The positive trend confirms the monetization of the company's scientific achievements. It is critical for investors to correlate this growth with the debt load to avoid overpaying.